Feature | September 04, 2014

Medtronic Announces CE Mark for Recapturable CoreValve Evolut R System

Next-generation TAVI system offers ability to reapture and reposition during deployment

September 4, 2014 — Medtronic announced CE mark for the 23 mm CoreValve Evolut R system for transcatheter aortic valve implantation (TAVI). The novel self-expanding valve and 14 French equivalent delivery system offers new capabilities that advance valve performance and deliverability during the procedure, while providing the option to recapture and reposition the valve during deployment phase if needed.

“The CoreValve Evolut R system offers improvements to a proven TAVI technology platform,” said Eberhard Grube, M.D., head of the Center of Innovative Interventions in Cardiology (CIIC), University Hospital Bonn, Germany. “The system’s new recapture-enabled capabilities and advancements in valve delivery provide physicians with added procedural confidence. It’s a significant advance to know there is the option to redeploy the valve in the ideal position if necessary.”

The novel system, consisting of the CoreValve Evolut R transcatheter aortic valve and the EnVeo R delivery catheter system, is designed for first-time positioning accuracy and also offers a new InLine sheath that significantly reduces the profile to the lowest on the market (14 French equivalent, less than 1/5 inch), as a smaller profile size is believed to minimize the risk of major vascular complications. The new valve is anatomically designed to increase conformability at the annulus for optimal annular fit and sealing, while maintaining supra-annular valve position for improved hemodynamic performance.

“Built on the proven foundation and procedural success of the CoreValve system with more than 65,000 implants worldwide, the CoreValve Evolut R system is the future of transcatheter aortic valve replacement,” said Rhonda Robb, vice president and general manager, Heart-Valve Therapies, Medtronic. “CoreValve Evolut R provides heart teams with meaningful advancements that will increase the potential for optimal device placement.”

The 23 mm CoreValve Evolut R transcatheter valve and EnVeo R delivery catheter system are now available in Europe and other countries that recognize the CE mark. It is not approved for commercial use in the United States, where it is currently undergoing clinical trials.

For more information: www.medtronic.com

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init